Immunocore Holdings (IMCR) Accounts Payables (2019 - 2026)

Immunocore Holdings (IMCR) has reported Accounts Payables for 8 consecutive years, with $30.2 million the latest figure, recorded in Q1 2026.

• Quarterly Accounts Payables rose 3.61% year-over-year to $30.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.2 million (up 3.61% YoY) and the FY2025 annual result came in at $24.4 million, down 2.93% from the prior year.
• Accounts Payables rose to $30.2 million in Q1 2026 per IMCR's latest filing, from $24.4 million in the prior quarter.
• Over the last five years, Accounts Payables for IMCR reached as high as $107.3 million in Q2 2023 and fell as low as $15.5 million in Q1 2024.
• A 5-year average of $38.5 million and a median of $24.4 million in 2025 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2024 — Accounts Payables tumbled 81.41% — and 2025, when it jumped 87.76%.
• Year by year, Accounts Payables stood at $88.1 million in 2022, then plunged by 79.79% to $17.8 million in 2023, then surged by 41.03% to $25.1 million in 2024, then retreated by 2.93% to $24.4 million in 2025, then climbed by 23.78% to $30.2 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $30.2 million, $24.4 million, and $23.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.